Lawyers See Potential for Xarelto Mass Tort

, The Legal Intelligencer

   | 2 Comments

With litigation surrounding the blood thinner Xarelto in its infancy, some lawyers examining cases said the litigation could expand to mass-tort proportions while others said it's too early to tell.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to LexisAdvance®.

Continue to LexisAdvance®

Not a LexisAdvance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via LexisAdvance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

What's being said

  • Greg

    "Instead of controlling bleeding, which is what it claims to do, it actually makes bleeding worse," Bern said.

    This class of drugs prevents blood clotting, not bleeding. Completely opposite descriptions. Your lack of understanding of the subject makes it very confusing for readers. The drugs are designed to stop blood clotting and blood clot formation which ultimately causes strokes. The side effect of uncontrolled bleeding is the result of the effects of the anti-coagulating properties of these drugs. Your comments are saying the drugs was designed to control bleeding which is completely wrong.

  • Gail

    Coumadin went off patent in over 25 years ago. What has happened in the blood thinning arena is Coumadin requires monthly monitoring for the INR where as the newer blood thinners do not. Also the new anticouagulants work on a different area of (X factors) to reduce clot formation.

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202669104379

Thank you!

This article's comments will be reviewed.